Chlorprothixene

證據等級: L5

預測適應症: 10 個

Chlorprothixene: From Psychosis to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Chlorprothixene is the first thioxanthene-class neuroleptic, introduced in 1959 under the brand names Taractan and Truxal, and has been used historically to treat psychosis, schizophrenia, and acute agitation. The TxGNN model's top prediction is that it may be effective for Retinal Dystrophy with or without Extraocular Anomalies, with 0 clinical trials and 15 retrieved publications — none of which directly study chlorprothixene in this condition, and the mechanistic link is not supported. A more clinically plausible secondary prediction exists for Manic Bipolar Affective Disorder (rank 10, L4), where historical psychiatric literature and pharmacological rationale are both present.

Quick Overview

Item	Content
Original Indication	Psychosis / Schizophrenia (thioxanthene-class antipsychotic; no SFDA registration found)
Predicted New Indication	Retinal Dystrophy with or without Extraocular Anomalies
TxGNN Prediction Score	99.9981%
Evidence Level	L5
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, chlorprothixene is the first marketed neuroleptic of the thioxanthene chemical class. Its primary pharmacological mechanism is dopamine D2 receptor antagonism, which reduces excessive dopaminergic signalling in mesolimbic pathways. Supplementary histamine H1 antagonism contributes to its pronounced sedative effect. These properties made it a first-generation antipsychotic for treating schizophrenia, psychotic agitation, and acute manic episodes in the pre-atypical antipsychotic era.

The predicted indication — retinal dystrophy with or without extraocular anomalies — is a genetically heterogeneous group of inherited photoreceptor and retinal pigment epithelium (RPE) degenerations. There is no established mechanistic pathway connecting D2 or H1 receptor antagonism to retinal photoreceptor maintenance or RPE survival. More critically, thioxanthene drugs share structural similarity with phenothiazines, a class definitively known to cause drug-induced retinopathy (most notably thioridazine-associated pigmentary retinopathy). This class-level concern inverts the direction of expected drug–disease interaction and substantially undermines the prediction's clinical plausibility.

The high TxGNN score (99.9981%) most likely reflects indirect graph-distance connections between pharmacological class nodes and disease taxonomy nodes in the knowledge graph, rather than a direct pharmacological relationship. The 15 retrieved publications cover general ophthalmological topics — orbital infections, congenital ptosis, cranial dysinnervation disorders, optic disc anomalies — without a single paper examining chlorprothixene as a therapy for retinal dystrophy. This prediction is assessed as not biologically plausible at current evidence level.

Note on Rank 10 — Manic Bipolar Affective Disorder (Score 99.9583%, L4): This lower-ranked prediction carries substantially stronger mechanistic credibility. D2 receptor antagonism is the core pharmacological mechanism for acute manic episode control, identical in principle to haloperidol and chlorpromazine. Historical literature from 1963–1980 (PMID 14085189, 7367466, 4471029) documents clinical use of chlorprothixene specifically in manic patients. However, no modern RCTs exist to meet contemporary evidence standards, and the drug is not marketed in Saudi Arabia.

Clinical Trial Evidence

Currently no related clinical trials registered for chlorprothixene in retinal dystrophy with or without extraocular anomalies.

Literature Evidence

The following publications were retrieved against the search query for chlorprothixene and retinal dystrophy. None directly study chlorprothixene as a treatment for this condition. They represent background ophthalmological literature on extraocular anomalies and related conditions retrieved by disease-term matching.

PMID	Year	Type	Journal	Key Findings
33806565	2021	Cohort/Observational	Int J Mol Sci	Retinal and optic nerve head abnormalities in congenital fibrosis of the extraocular muscles (CFEOM); KIF21A and TUBB3 mutations extend beyond oculomotor dysinnervation to retinal ganglion cells
38321238	2024	Review	Pediatric Radiology	Differential diagnosis and imaging features of pediatric ocular pathologies including retinopathy of prematurity, Coats disease, and congenital/developmental anomalies
36892533	2023	Clinical Genetics	Invest Ophthalmol Vis Sci	Monoallelic MAB21L1 missense mutations causing autosomal dominant BAMD syndrome (blepharophimosis plus anterior segment and macular dysgenesis)
38249493	2023	Review	Taiwan J Ophthalmol	Congenital lens shape anomalies and their association with anterior segment dysgenesis and persistent fetal vasculature
24932988	2014	Review	Am J Ophthalmol	Unifying pathogenesis theory for maculopathy associated with cavitary optic disc anomalies; proposed surgical approach for durable cure
30196776	2018	Review	J Binocul Vis Ocul Motil	Classification and diagnostic approach to congenital cranial dysinnervation disorders (CCDDs) including ophthalmoplegia subtypes
22241537	2012	Review	Klin Monbl Augenheilkd	Congenital ptosis: levator muscle dystrophy and fibrosis, association with refractive errors and binocular vision disturbance
7035111	1981	Review	Doc Ophthalmol	Wagner-Stickler syndrome complex: vitreoretinal degeneration, myopia, retinal detachment, and associated systemic extraocular manifestations
9416661	1997	Review	Semin Ultrasound CT MR	Orbital infections secondary to sinusitis: five-stage cellulitis classification, systemic predisposing conditions, clinical signs
20127583	2010	Review	Semin Neurol	Systematic approach to diplopia evaluation: history, examination, and differential diagnosis of ocular motility disorders

Saudi Arabia Market Information

Chlorprothixene has no regulatory authorizations in Saudi Arabia. The SFDA query returned zero results. This drug is not marketed and no licensed products exist in the Saudi market.

Safety Considerations

Please refer to the package insert for safety information.

Class-level safety concern relevant to this prediction: Thioxanthene and phenothiazine antipsychotics carry established risk of drug-induced retinal toxicity. Thioridazine (a structurally related phenothiazine) is a well-documented cause of irreversible pigmentary retinopathy; this risk is shared across the antipsychotic drug class to varying degrees. Using chlorprothixene in a patient with pre-existing retinal dystrophy would require careful ophthalmological monitoring, and the drug's potential to worsen photoreceptor function directly contradicts the premise of treating retinal dystrophy. This safety signal must be resolved before any exploration of this indication proceeds.

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN prediction (retinal dystrophy) has no mechanistic basis, no clinical trial evidence, and the drug's pharmacological class is associated with causing retinal toxicity rather than treating it — making this prediction not currently actionable. The drug is also not marketed in Saudi Arabia, with zero SFDA authorizations and no available safety dossier.

To proceed on any indication, the following is needed:

MOA data: Obtain full DrugBank pharmacology profile for chlorprothixene (DrugBank ID: DB01239) to verify receptor binding profile and known pharmacodynamic effects
Safety dossier: Retrieve package insert warnings, contraindications, and DDI data — all currently data gaps; the retinopathy class-effect risk requires formal characterisation before any ophthalmological indication can be considered
For retinal dystrophy (rank 1): A biologically plausible mechanistic hypothesis is required before any evidence generation; absent one, this indication should be deprioritised
For manic bipolar affective disorder (rank 10, L4): This is the most scientifically defensible repurposing candidate; pursue a retrospective chart review or pharmacoepidemiological study using existing real-world data, then evaluate feasibility of an investigator-initiated trial
Saudi Arabia market pathway: Any development programme requires establishing a regulatory pathway from zero (no existing SFDA approval); consider alignment with a licensed thioxanthene product already registered in comparable markets (EU, Japan) to leverage bridging data
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.